Boston Center for Memory
Boston Center for Memory
Newton, Massachusetts, United States15 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies | Alzheimer disease, Cognition Disorders, Cognitive Dysfunction, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Recruiting | Phase 3 | 2026-10-09 | NCT07177352 | |
| A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3) | Alzheimer disease, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Active, not recruiting | Phase 3 | 2026-10-07 | NCT06653153 | |
| A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease | Alzheimer disease, Cognition Disorders, Cognitive Dysfunction, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Recruiting | Phase 3 | 2026-10-06 | NCT06976216 | |
| A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | Alzheimer disease, Cognition Disorders, Cognitive Dysfunction, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Active, not recruiting | Phase 3 | 2026-10-06 | NCT03887455 | |
| A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) | Alzheimer disease, Dyskinesias, Neurobehavioral Manifestations, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Psychomotor Agitation, Psychomotor Disorders, Signs and Symptoms, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Recruiting | Phase 3 | 2026-09-28 | NCT06937229 | |
| A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease | Alzheimer disease, Cognition Disorders, Cognitive Dysfunction, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Active, not recruiting | Phase 3 | 2026-09-25 | NCT07169578 | |
| A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1) | Alzheimer disease, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Recruiting | Phase 3 | 2026-09-16 | NCT07011732 | |
| A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2) | Alzheimer disease, Cognition Disorders, Cognitive Dysfunction, Pathological Conditions, Anatomical, Pathological Conditions, Signs and Symptoms, Plaque, Amyloid, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Active, not recruiting | Phase 3 | 2026-08-26 | NCT04437511 | |
| A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT). | Alzheimer disease, Pathological Conditions, Anatomical, Pathological Conditions, Signs and Symptoms, Plaque, Amyloid, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Recruiting | Phase 3 | 2026-07-07 | NCT07602582 | |
| A Study to Learn About the Safety of Diranersen (BIIB080) Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age | Alzheimer's Disease Dementia; Mild Cognitive Impairment Due to Alzheimer's Disease | Active, not recruiting | Phase 2 | 2026-06-30 | NCT05399888 | |
| A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3) | Alzheimer disease, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Active, not recruiting | Phase 3 | 2026-01-21 | NCT05026866 | |
| A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD) | Alzheimer disease, Cognition Disorders, Cognitive Dysfunction, Memory Disorders, Neurobehavioral Manifestations, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Active, not recruiting | Phase 2 | 2025-10-27 | NCT06335173 | |
| Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD) | Alzheimer disease, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Active, not recruiting | Phase 3 | 2025-10-02 | NCT05531526 | |
| Extension to a Pivotal Study of Sensory Stimulation in Alzheimer's Disease (OLE Hope Study, CA-0015) | Alzheimer disease, Cognition Disorders, Cognitive Dysfunction, Hemic and Lymphatic Diseases, Mild Cognitive Impairment, Neoplasms by Histologic Type, brain disorder, central nervous system disorder, cognitive disorder, dementia, follicular lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Enrolling by invitation | Not applicable | 2024-05-07 | NCT06245031 | |
| Multi-Center Study of Sensory Stimulation to Improve Brain Function | Alzheimer disease, Cognition Disorders, Cognitive Decline, Cognitive Dysfunction, Hemic and Lymphatic Diseases, Mild Cognitive Impairment, Neoplasms by Histologic Type, brain disorder, central nervous system disorder, cognitive disorder, dementia, follicular lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Active, not recruiting | Not applicable | 2021-08-24 | NCT03556280 |